There are 2137 resources available
435P - Bevacizumab (bev) continuation with FOLFIRI or switch to aflibercept (afli) with FOLFIRI as second-line treatment (L2) after first line of FOLFOX-bev (L1) for metastatic colorectal cancer (mCRC): An AGEO multicenter study
Presenter: Cecile Torregrosa
Session: E-Poster Display
Resources:
Abstract
436P - Phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second line treatment of KRAS-mutated metastatic colorectal cancer
Presenter: Daniel Ahn
Session: E-Poster Display
Resources:
Abstract
437P - Designing clinical profiles that influence the discordance of RAS mutations in blood and tissue: Sidedness and anatomical metastasis as factors of disagreement
Presenter: Elena Brozos-Vázquez
Session: E-Poster Display
Resources:
Abstract
438P - Interim safety analysis of the phase IIb study of ramucirumab in combination with TAS102 vs. TAS102 monotherapy in metastatic colorectal cancer: The RAMTAS trial of the German AIO
Presenter: Stefan Kasper
Session: E-Poster Display
Resources:
Abstract
439P - Phase Ib/II study of ibrutinib (ibr) in combination with cetuximab (cetux) in patients (pts) with previously treated metastatic colorectal cancer (mCRC)
Presenter: Do-Youn Oh
Session: E-Poster Display
Resources:
Abstract
440P - Phase III randomized trial comparing short-term infusion of oxaliplatin and capecitabine (Xelox30) with chronomodulated (Xelox30) in patients with advanced and/or metastatic colorectal cancer
Presenter: Mona Nafea
Session: E-Poster Display
Resources:
Abstract
441P - Evaluation of conversion therapy in patients undergoing secondary resection of metastases in curative intent within the FIRE-3 (AIO KRK-0306) study
Presenter: Jobst von Einem
Session: E-Poster Display
Resources:
Abstract
442P - Camrelizumab combined with apatinib in the treatment of patients with advanced gastric cancer and colorectal cancer: One-arm exploratory clinical trial
Presenter: Li Xiao
Session: E-Poster Display
Resources:
Abstract
443P - First-line chemotherapy with raltitrexed in metastatic colorectal cancer: An AGEO multicentre study
Presenter: Claire Gallois
Session: E-Poster Display
Resources:
Abstract
444P - PRODIGE 25 (FFCD 11-01)-FOLFA: A randomized phase II trial evaluating aflibercept associated with LV5FU2 regimen as first-line treatment of non-resectable metastatic colorectal cancers
Presenter: Jean Louis Legoux
Session: E-Poster Display
Resources:
Abstract